Telix Pharmaceuticals Limited (TLPPF)
USD 16.5
(-0.65%)
USD 16.5
(-0.65%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 251.22 Million AUD | 43.27% |
| 2022 | 175.34 Million AUD | 62.88% |
| 2021 | 107.65 Million AUD | 36.61% |
| 2020 | 78.8 Million AUD | 142.28% |
| 2019 | 32.52 Million AUD | 36.65% |
| 2018 | 23.8 Million AUD | 1221.74% |
| 2017 | 1.8 Million AUD | 0.0% |
| 2000 | 352 Thousand AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 248.82 Million AUD | -34.94% |
| 2024 Q2 | 341.98 Million AUD | 110.76% |
| 2023 Q4 | 251.22 Million AUD | 0.73% |
| 2023 Q1 | 234.27 Million AUD | 33.61% |
| 2023 Q2 | 231.83 Million AUD | -1.04% |
| 2023 Q3 | 249.39 Million AUD | 7.57% |
| 2023 FY | 251.22 Million AUD | 43.27% |
| 2022 Q4 | 175.34 Million AUD | 0.0% |
| 2022 Q2 | 109.28 Million AUD | -1.13% |
| 2022 Q3 | 175.34 Million AUD | 60.44% |
| 2022 Q1 | 110.53 Million AUD | 2.67% |
| 2022 FY | 175.34 Million AUD | 62.88% |
| 2021 Q3 | 107.65 Million AUD | 34.81% |
| 2021 Q4 | 107.65 Million AUD | 0.0% |
| 2021 Q2 | 79.85 Million AUD | -1.3% |
| 2021 Q1 | 80.91 Million AUD | 2.67% |
| 2021 FY | 107.65 Million AUD | 36.61% |
| 2020 Q3 | 78.8 Million AUD | 76.68% |
| 2020 Q1 | 40.14 Million AUD | 23.41% |
| 2020 Q4 | 78.8 Million AUD | 0.0% |
| 2020 FY | 78.8 Million AUD | 142.28% |
| 2020 Q2 | 44.6 Million AUD | 11.11% |
| 2019 FY | 32.52 Million AUD | 36.65% |
| 2019 Q1 | 22.29 Million AUD | -6.32% |
| 2019 Q2 | 22.29 Million AUD | 0.0% |
| 2019 Q4 | 32.52 Million AUD | 0.0% |
| 2019 Q3 | 32.52 Million AUD | 45.87% |
| 2018 Q1 | 3.77 Million AUD | 157.24% |
| 2018 FY | 23.8 Million AUD | 1221.74% |
| 2018 Q4 | 23.8 Million AUD | -0.0% |
| 2018 Q3 | 23.8 Million AUD | 530.16% |
| 2018 Q2 | 3.77 Million AUD | 0.0% |
| 2017 FY | 1.8 Million AUD | 0.0% |
| 2017 Q2 | 458 Thousand AUD | 0.0% |
| 2017 Q3 | 1.46 Million AUD | 220.62% |
| 2017 Q4 | 1.46 Million AUD | 0.0% |
| 2017 Q1 | 458 Thousand AUD | 0.0% |
| 2000 FY | 352 Thousand AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | -399.809% |
| Skye Bioscience, Inc. | 14.07 Million USD | -1685.247% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -325.702% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -30961.556% |
| Qrons Inc. | 1.48 Million USD | -16775.247% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -561972.669% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -2553.984% |
| BioStem Technologies, Inc. | 15.9 Million USD | -1479.562% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4503.182% |
| CSL Limited | 18.62 Billion USD | 98.651% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -235.323% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -246.655% |
| Rebus Holdings, Inc. | 5.24 Million USD | -4692.522% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -915672.974% |
| Neon Bloom, Inc. | 1.22 Million USD | -20387.795% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -124814.974% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -371.295% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -2521.827% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -59492.758% |
| SQZ Biotechnologies Company | 50.03 Million USD | -402.056% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1992.005% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -6422.886% |
| Mesoblast Limited | 188.44 Million USD | -33.314% |
| Marizyme, Inc. | 26.67 Million USD | -841.771% |
| Genus plc | 485 Million USD | 48.201% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -4199.851% |
| Pharming Group N.V. | 244.07 Million USD | -2.93% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -12397.898% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -9883.754% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -6511.158% |
| ContraFect Corporation | 32.53 Million USD | -672.26% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -12579.705% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -6463.404% |
| IMV Inc. | 37.93 Million USD | -562.287% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -2032.958% |
| MultiCell Technologies, Inc. | 1617.67 USD | -15529890.666% |
| ONE Bio Corp. | 27.49 Million USD | -813.681% |
| Accustem Sciences Inc. | 1.07 Million USD | -23177.884% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -224.508% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -11777.816% |
| Q BioMed Inc. | 8.13 Million USD | -2988.969% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -202.917% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -4781.895% |
| Biomind Labs Inc. | 1.49 Million USD | -16663.779% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -111.607% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -2678.352% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -1265.094% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -17420.806% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -176700.028% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -4272.291% |
| GB Sciences, Inc. | 5.41 Million USD | -4537.219% |
| Alpha Cognition Inc. | 7.16 Million USD | -3406.377% |
| HST Global, Inc. | 593.59 Thousand USD | -42222.602% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -19851.191% |
| Halberd Corporation | 728.71 Thousand USD | -34374.743% |
| Enzolytics Inc. | 365.26 Million USD | 31.222% |
| Agentix Corp. | 2.51 Million USD | -9906.712% |
| Resverlogix Corp. | 67.39 Million USD | -272.758% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -29852.834% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 43.539% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -14557.176% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -915.209% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -2010.576% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -6754.373% |
| AVAX Technologies, Inc. | 3.99 Million USD | -6190.437% |
| Zenith Capital Corp. | 27.56 Thousand USD | -911155.396% |
| Genscript Biotech Corporation | 1.32 Billion USD | 81.052% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -105167.039% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -6627.462% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -36799.45% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -9164.648% |
| Kadimastem Ltd | 3.5 Million USD | -7067.861% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -375258.962% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -53961.661% |
| LadRx Corporation | 2.2 Million USD | -11316.533% |
| Cell Source, Inc. | 15.8 Million USD | -1489.35% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4503.182% |
| NovAccess Global Inc. | 7.86 Million USD | -3095.936% |
| Affymax, Inc. | 8.87 Million USD | -2731.969% |
| Itoco Inc. | 1.65 Million USD | -15096.676% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -12145.481% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -4053.149% |
| Mobile Lads Corp. | 1.31 Million USD | -19026.347% |
| CytoDyn Inc. | 127.89 Million USD | -96.431% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -600928.733% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -15938.54% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -2174.49% |
| SYBLEU INC | 681.41 Thousand USD | -36768.096% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -4017.14% |
| International Stem Cell Corporation | 5.27 Million USD | -4660.735% |
| Bioxytran, Inc. | 3.24 Million USD | -7631.159% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -40043.878% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -5341.135% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -512.801% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1028.336% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -12303.753% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -4486.053% |
| Neutra Corp. | 973.52 Thousand USD | -25705.497% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -765.842% |
| PureTech Health plc | 125.58 Million USD | -100.046% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -6586.602% |
| IXICO plc | 1.9 Million USD | -13120.284% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1123.752% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -143.142% |
| CSL Limited | 18.62 Billion USD | 98.651% |
| Cellectis S.A. | 249.36 Million USD | -0.744% |